-The Hindu Business Line Mumbai: A fresh bout of opposition has been filed against Gilead's patent application on hepatitis c drug sofosbuvir. This comes close on the heels of a spate of developments involving the drug, last month. Non-government organisation Sankalp Rehabilitation Trust, represented by the Lawyers Collective has filed a pre-grant opposition on the drug in the Delhi patent office. (A pre-grant opposition allows interested parties to oppose a patent application...

-The Times of India NEW DELHI: The government may negotiate prices of patented medicines with their manufacturers before allowing pharmaceutical companies to launch them in India. The move, a first of its kind, is also likely to be applied on patented drugs that are already being sold in the country, an official source said. An inter-ministerial committee, evaluating the mechanism to negotiate prices of patented medicines, has recently sought detailed information about...

-Down to Earth US actions jeopardise India's pro-poor patent laws that promote generic drugs production, says online global petition More than 75,000 people have requested Prime Minister Narendra Modi not to succumb to US pressure on Intellectual Property Rights (IP). With trade and intellectual property rights featuring prominently in the agenda of US president Barak Obama's India visit, civil society groups have expressed concern that talks on these issues are designed to make...

-The Telegraph New Delhi: India's patent regulating agency today rejected a US company's patent claim on a drug to treat hepatitis C, raising hopes that generic drug makers could now produce cheaper versions of the medicine. The Indian Patents Controller has denied a patent to sofosbuvir from Gilead, a US biopharmaceutical company that had last year pledged to make the oral drug available in India and 90 other developing countries at $900...

-The Financial Express With 66% of its population under the age of 35, India is home to the largest cohort of young people in the world-825 million. The median age of the country is just 27 years, much below 37 in the US and 46 in Japan. Numbers like these suggest that India has a competitive advantage over China and other Asian countries-a demographic dividend. But favourable demographics do not imply that...